Key Points
- General Counsel John Brottem sold 2,632 Outset Medical shares at an average price of $4.39, worth $11,554.48. The sale covered tax-withholding obligations tied to vested equity awards and reduced his holdings by 2.92%.
- Outset Medical shares were down 7.3%, opening at $4.18, while the company reported a quarterly loss of $0.80 per share—worse than the $0.72 analyst estimate—despite revenue exceeding expectations.
- Analyst sentiment is mixed, with three Buy, one Hold and one Sell rating; the consensus is Hold with a $10.00 price target, compared with the stock’s roughly $4.18 trading price.
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) General Counsel John Brottem sold 2,632 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $4.39, for a total transaction of $11,554.48. Following the transaction, the general counsel owned 87,475 shares of the company's stock, valued at approximately $384,015.25. This trade represents a 2.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Outset Medical Stock Down 7.3%
NASDAQ OM opened at $4.18 on Wednesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11. The company's 50 day simple moving average is $4.57 and its 200 day simple moving average is $4.23. Outset Medical, Inc. has a 12 month low of $3.00 and a 12 month high of $16.16. The company has a market capitalization of $78.58 million, a P/E ratio of -1.02 and a beta of 1.96.
Outset Medical (NASDAQ:OM - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.08). The business had revenue of $31.64 million for the quarter, compared to the consensus estimate of $28.97 million. Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%. Equities research analysts expect that Outset Medical, Inc. will post -3.8 earnings per share for the current fiscal year.
Institutional Trading of Outset Medical
Large investors have recently added to or reduced their stakes in the company. BML Capital Management LLC purchased a new position in shares of Outset Medical during the fourth quarter valued at $2,015,000. Renaissance Technologies LLC boosted its position in Outset Medical by 391.3% during the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company's stock worth $853,000 after acquiring an additional 176,870 shares during the period. R Squared Ltd purchased a new position in Outset Medical during the 1st quarter valued at about $65,000. Aristides Capital LLC acquired a new position in shares of Outset Medical in the 4th quarter valued at about $177,000. Finally, Sei Investments Co. boosted its holdings in shares of Outset Medical by 15.5% during the first quarter. Sei Investments Co. now owns 35,366 shares of the company's stock worth $136,000 after purchasing an additional 4,738 shares during the period.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on OM shares. Weiss Ratings raised Outset Medical from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 7th. Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a report on Saturday. Finally, TD Cowen reiterated a "buy" rating on shares of Outset Medical in a research report on Friday, May 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Outset Medical has a consensus rating of "Hold" and a consensus target price of $10.00.
Read Our Latest Analysis on Outset Medical
Outset Medical Company Profile
(
Get Free Report)
Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
